Connote Healthcare Private Limited

Vildagliptin 50 mg + Metformin 1000 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus. This tablet is typically prescribed when blood sugar levels are not adequately controlled by diet, exercise, or monotherapy. It combines two complementary antidiabetic agents:

1. Vildagliptin (DPP-4 Inhibitor / Gliptin): This component works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). By doing so, it enhances the levels of naturally occurring incretin hormones (like GLP-1 and GIP). These hormones increase glucose-dependent insulin secretion from the pancreas and reduce glucagon secretion, leading to better control of both fasting and post-meal blood sugar levels.

2. Metformin (Biguanide): This component primarily acts by:

   • Reducing the amount of glucose produced by the liver.
   • Decreasing the absorption of glucose from the intestines.
   • Improving the body's sensitivity to insulin, allowing cells to utilize glucose more efficiently.

This combination provides a comprehensive approach to diabetes management by improving both insulin release and the body's response to insulin, without typically causing weight gain.

Key Features:

• Dual-Action Formula: Combines two distinct mechanisms for robust blood glucose control.
• Glucose-Dependent Insulin Release: Vildagliptin stimulates insulin only when blood sugar is high, reducing hypoglycemia risk.
• Improved Insulin Sensitivity: Metformin component enhances the body's use of insulin.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen.
• Weight Neutrality: Generally does not cause weight gain.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Vildagliptin IP: 50 mg
• Metformin Hydrochloride IP: 1000 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with metformin or vildagliptin monotherapy, or who are already being treated with both medications separately. It can also be used in combination with other diabetes medicines, including insulin.

Sitagliptin 25 mg tablets are an oral antidiabetic medication that belongs to a class of drugs called Dipeptidyl Peptidase-4 (DPP-4) inhibitors, also known as "gliptins." It is prescribed for the management of Type 2 Diabetes Mellitus in adults. This lower dose is typically used for patients with kidney impairment or for initial titration to ensure proper glycemic control with minimal side effects.

Mechanism of Action: Sitagliptin works by selectively inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). DPP-4 is an enzyme that rapidly breaks down naturally occurring incretin hormones in the body, primarily Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). By inhibiting DPP-4, Sitagliptin:

1. Increases Active Incretin Levels: It prolongs the activity and increases the circulating levels of active GLP-1 and GIP.
2. Enhances Glucose-Dependent Insulin Secretion: Higher incretin levels lead to increased insulin synthesis and release from pancreatic beta cells, but importantly, this effect is glucose-dependent (meaning insulin is released more effectively when blood sugar is high, and less so when blood sugar is low, reducing the risk of hypoglycemia).
3. Decreases Glucagon Secretion: GLP-1 also suppresses glucagon secretion from pancreatic alpha cells. Reduced glucagon levels, along with higher insulin levels, lead to reduced glucose production by the liver.

This dual action helps to control both fasting and post-meal blood sugar levels without typically causing weight gain.

Key Features:

• DPP-4 Inhibitor: A modern class of oral antidiabetic agents.
• Glucose-Dependent Action: Stimulates insulin release and suppresses glucagon only when blood sugar is elevated, leading to a low risk of hypoglycemia when used alone.
• Targets Incretin System: Enhances the body's natural mechanisms for glucose regulation.
• Weight Neutrality: Generally does not cause weight gain.
• Convenient Dosing: Typically taken once daily with or without food.
• Dose Adjustment for Renal Impairment: The 25 mg dose is specifically used for patients with severe kidney impairment.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Sitagliptin 50 mg tablets are an oral antidiabetic medication that belongs to a class of drugs called Dipeptidyl Peptidase-4 (DPP-4) inhibitors, also known as "gliptins." It is prescribed for the management of Type 2 Diabetes Mellitus in adults. This lower dose is typically used for patients with kidney impairment or for initial titration to ensure proper glycemic control with minimal side effects.

 

Mechanism of Action: Sitagliptin works by selectively inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). DPP-4 is an enzyme that rapidly breaks down naturally occurring incretin hormones in the body, primarily Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). By inhibiting DPP-4, Sitagliptin:

 

1. Increases Active Incretin Levels: It prolongs the activity and increases the circulating levels of active GLP-1 and GIP.
2. Enhances Glucose-Dependent Insulin Secretion: Higher incretin levels lead to increased insulin synthesis and release from pancreatic beta cells, but importantly, this effect is glucose-dependent (meaning insulin is released more effectively when blood sugar is high, and less so when blood sugar is low, reducing the risk of hypoglycemia).
3. Decreases Glucagon Secretion: GLP-1 also suppresses glucagon secretion from pancreatic alpha cells. Reduced glucagon levels, along with higher insulin levels, lead to reduced glucose production by the liver.

This dual action helps to control both fasting and post-meal blood sugar levels without typically causing weight gain.

 

Key Features:

• DPP-4 Inhibitor: A modern class of oral antidiabetic agents.
• Glucose-Dependent Action: Stimulates insulin release and suppresses glucagon only when blood sugar is elevated, leading to a low risk of hypoglycemia when used alone.
• Targets Incretin System: Enhances the body's natural mechanisms for glucose regulation.
• Weight Neutrality: Generally does not cause weight gain.
• Convenient Dosing: Typically taken once daily with or without food.
• Dose Adjustment for Renal Impairment: The 25 mg dose is specifically used for patients with severe kidney impairment.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Sitagliptin 100 mg tablets are an oral antidiabetic medication that belongs to a class of drugs called Dipeptidyl Peptidase-4 (DPP-4) inhibitors, also known as "gliptins." It is prescribed for the management of Type 2 Diabetes Mellitus in adults. This lower dose is typically used for patients with kidney impairment or for initial titration to ensure proper glycemic control with minimal side effects.

 

Mechanism of Action: Sitagliptin works by selectively inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). DPP-4 is an enzyme that rapidly breaks down naturally occurring incretin hormones in the body, primarily Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). By inhibiting DPP-4, Sitagliptin:

 

1. Increases Active Incretin Levels: It prolongs the activity and increases the circulating levels of active GLP-1 and GIP.
2. Enhances Glucose-Dependent Insulin Secretion: Higher incretin levels lead to increased insulin synthesis and release from pancreatic beta cells, but importantly, this effect is glucose-dependent (meaning insulin is released more effectively when blood sugar is high, and less so when blood sugar is low, reducing the risk of hypoglycemia).
3. Decreases Glucagon Secretion: GLP-1 also suppresses glucagon secretion from pancreatic alpha cells. Reduced glucagon levels, along with higher insulin levels, lead to reduced glucose production by the liver.

This dual action helps to control both fasting and post-meal blood sugar levels without typically causing weight gain.

 

Key Features:

• DPP-4 Inhibitor: A modern class of oral antidiabetic agents.
• Glucose-Dependent Action: Stimulates insulin release and suppresses glucagon only when blood sugar is elevated, leading to a low risk of hypoglycemia when used alone.
• Targets Incretin System: Enhances the body's natural mechanisms for glucose regulation.
• Weight Neutrality: Generally does not cause weight gain.
• Convenient Dosing: Typically taken once daily with or without food.
• Dose Adjustment for Renal Impairment: The 25 mg dose is specifically used for patients with severe kidney impairment.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Voglibose 0.3 mg + Metformin 500 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus in adults. This tablet is particularly useful when blood sugar levels are not adequately controlled by diet, exercise, and monotherapy. It combines two distinct antidiabetic agents to provide a synergistic effect:

1. Voglibose (Alpha-Glucosidase Inhibitor): This component works in the small intestine by delaying the digestion and absorption of carbohydrates. It inhibits alpha-glucosidase enzymes, which are responsible for breaking down complex sugars into absorbable glucose. This action primarily helps to reduce the sharp rise in blood sugar levels after meals (postprandial hyperglycemia).

2. Metformin (Biguanide): This component primarily acts by:

   • Reducing Hepatic Glucose Production: It decreases the amount of glucose produced and released by the liver.
   • Decreasing Intestinal Glucose Absorption: It further slows down the absorption of sugar from the foods consumed.
   • Increasing Insulin Sensitivity: It improves the body's response to its own insulin, allowing cells to utilize glucose more effectively. The Metformin component is often in a Sustained Release (SR) or Prolonged Release (PR) form (though not specified as SR/PR in your request, 500mg is a common immediate-release dose as well, often taken twice daily).

This combination provides a comprehensive approach to diabetes management by tackling both post-meal glucose spikes and overall glucose production/insulin sensitivity.

Key Features:

• Dual-Action Formula: Combines a post-meal glucose regulator (Voglibose) with an insulin sensitizer/glucose production reducer (Metformin).
• Targeted Postprandial Control: Voglibose specifically helps manage high blood sugar after meals.
• Comprehensive Glycemic Control: Addresses both fasting and post-meal blood sugar levels.
• Convenient Dosing: Fixed-dose combination simplifies the medication regimen.
• Potential for Weight Neutrality/Loss: Metformin generally does not cause weight gain and may aid in modest weight loss.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Voglibose 0.2 mg + Metformin 500 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus in adults. This tablet is particularly useful when blood sugar levels are not adequately controlled by diet, exercise, and monotherapy. It combines two distinct antidiabetic agents to provide a synergistic effect:

1. Voglibose (Alpha-Glucosidase Inhibitor): This component works in the small intestine by delaying the digestion and absorption of carbohydrates. It inhibits alpha-glucosidase enzymes, which are responsible for breaking down complex sugars into absorbable glucose. This action primarily helps to reduce the sharp rise in blood sugar levels after meals (postprandial hyperglycemia).

2. Metformin (Biguanide): This component primarily acts by:

   • Reducing Hepatic Glucose Production: It decreases the amount of glucose produced and released by the liver.
   • Decreasing Intestinal Glucose Absorption: It further slows down the absorption of sugar from the foods consumed.
   • Increasing Insulin Sensitivity: It improves the body's response to its own insulin, allowing cells to utilize glucose more effectively. The Metformin component is often in a Sustained Release (SR) or Prolonged Release (PR) form (though not specified as SR/PR in your request, 500mg is a common immediate-release dose as well, often taken twice daily).

This combination provides a comprehensive approach to diabetes management by tackling both post-meal glucose spikes and overall glucose production/insulin sensitivity.

Key Features:

• Dual-Action Formula: Combines a post-meal glucose regulator (Voglibose) with an insulin sensitizer/glucose production reducer (Metformin).
• Targeted Postprandial Control: Voglibose specifically helps manage high blood sugar after meals.
• Comprehensive Glycemic Control: Addresses both fasting and post-meal blood sugar levels.
• Convenient Dosing: Fixed-dose combination simplifies the medication regimen.
• Potential for Weight Neutrality/Loss: Metformin generally does not cause weight gain and may aid in modest weight loss.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Acarbose 50 mg tablets are an oral antidiabetic medication belonging to the class of alpha-glucosidase inhibitors. It is primarily used for the management of Type 2 Diabetes Mellitus in adults. Its main role is to help control the surge in blood sugar levels that occurs immediately after meals (postprandial hyperglycemia). This low-strength dosage is often used for initial titration to minimize gastrointestinal side effects.

Mechanism of Action: Acarbose works locally in the small intestine by reversibly inhibiting alpha-glucosidase enzymes. These enzymes are crucial for breaking down complex carbohydrates (polysaccharides, oligosaccharides, and disaccharides like starch and table sugar) into simpler absorbable sugars (monosaccharides like glucose). By inhibiting these enzymes, Acarbose delays the digestion and absorption of carbohydrates, which effectively flattens the post-meal rise in blood glucose. It does not directly affect insulin secretion or insulin sensitivity.

Key Features:

• Targets Post-Meal Blood Sugar: Specifically designed to reduce glucose spikes after meals.
• Unique Mechanism: Works by delaying carbohydrate digestion, making it complementary to other diabetes medications.
• Low Risk of Hypoglycemia (alone): Generally does not cause low blood sugar when used as monotherapy, as it does not stimulate insulin release.
• Initial Dose Strength: The 25 mg strength is suitable for starting therapy, allowing for gradual dose adjustments to improve tolerability.
• Oral Administration: Convenient tablet form for daily use.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Acarbose IP: 50 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control, particularly postprandial blood glucose levels, in adults.
• It can be used as monotherapy or in combination with other oral hypoglycemic agents (e.g., Metformin, Sulfonylureas) or insulin, especially when after-meal glucose levels are difficult to control.

The Pioglitazone Hydrochloride 30 mg + Metformin Hydrochloride (ER) 500 mg Tablet is a dual-combination oral medication designed for the comprehensive management of Type 2 Diabetes Mellitus in adults. This tablet is typically prescribed when blood sugar levels are not adequately controlled by diet, exercise, and monotherapy with either pioglitazone or metformin, or when patients are already stable on both components taken separately. This formulation combines two potent antidiabetic agents with distinct mechanisms of action:

1. Pioglitazone (Thiazolidinedione - TZD): This component works as an insulin sensitizer. It activates Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor found in tissues crucial for insulin action (like fat, muscle, and liver). Activation of PPARγ leads to:

   • Increased Insulin Sensitivity: Cells become more responsive to insulin, enhancing glucose uptake and utilization by peripheral tissues.
   • Reduced Hepatic Glucose Output: Decreases the amount of glucose produced and released by the liver. Pioglitazone's action is dependent on the presence of insulin, but it does not directly stimulate insulin secretion, thus having a low risk of hypoglycemia when used alone.

2. Metformin Hydrochloride (Biguanide) - Extended Release (ER): The Metformin component acts by:

   • Reducing Hepatic Glucose Production: It significantly decreases the amount of glucose produced and released by the liver.
   • Decreasing Intestinal Glucose Absorption: It slows down the absorption of sugar from the foods consumed in the intestines.
   • Increasing Insulin Sensitivity: It further improves the body's response to its own insulin, allowing cells to utilize glucose more efficiently. The Extended Release (ER) formulation ensures a gradual and prolonged release of metformin, providing more consistent blood sugar control over 24 hours and often improving gastrointestinal tolerability compared to immediate-release forms.

This combination offers a robust approach to diabetes management by tackling both insulin resistance and excessive glucose production, addressing key pathophysiological defects in Type 2 Diabetes.

Key Features:

• Dual-Action Formula: Combines an insulin sensitizer (Pioglitazone) with an insulin sensitizer/glucose production reducer (Metformin) for synergistic effects.
• Comprehensive Glycemic Control: Effectively lowers both fasting and post-meal blood sugar levels.
• Addresses Insulin Resistance: Directly targets a root cause of Type 2 Diabetes.
• Extended Release Metformin: Provides prolonged action and often reduces common GI side effects.
• Convenient Dosing: Fixed-dose combination in a single ER tablet simplifies the medication regimen.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Pioglitazone Hydrochloride IP equivalent to Pioglitazone: 30 mg
• Metformin Hydrochloride IP: 500 mg (as Extended Release)
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with either metformin or pioglitazone monotherapy, or who are already being treated with both medications separately.

Repaglinide 1 mg tablets are an oral antidiabetic medication belonging to the meglitinide class (also known as "glinides"). It is primarily used for the management of Type 2 Diabetes Mellitus in adults. This medication is particularly effective at controlling post-meal (postprandial) blood sugar spikes due to its rapid onset and short duration of action.

Mechanism of Action: Repaglinide works by stimulating the beta cells in the pancreas to release insulin. Similar to sulfonylureas, it binds to specific receptors on these cells (ATP-dependent potassium channels, SUR1), causing their closure. This depolarization of the beta cell membrane leads to calcium influx and subsequent release of insulin. However, Repaglinide's action is glucose-dependent and has a faster onset and shorter duration compared to sulfonylureas, making it ideal for targeting mealtime glucose excursions.

Key Features:

• Rapid-Acting Insulin Secretagogue: Quickly stimulates insulin release in response to a meal, effectively controlling post-meal blood sugar.
• Targets Postprandial Hyperglycemia: Specifically designed to manage the rise in blood sugar levels that occurs after eating.
• Flexible Dosing: Taken before each main meal, allowing for flexibility if a meal is skipped (the dose should also be skipped).
• Low Initial Dose: The 1 mg strength is suitable for initiating therapy, especially for patients with lower HbA1c or who are sensitive to medications.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Glimepiride 0.5 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is used for the management of Type 2 Diabetes Mellitus in adults. This lower strength is particularly useful for initiating therapy, for patients requiring a milder dose to achieve glycemic control, or as part of a combination regimen.

 

Mechanism of Action: Glimepiride primarily works by stimulating the beta cells in the pancreas to release more insulin. It achieves this by binding to specific receptors on these cells, which leads to the closure of ATP-sensitive potassium channels. This triggers a cascade of events that cause the pancreatic beta cells to depolarize and release insulin. The increased insulin in the bloodstream helps to lower blood glucose by facilitating glucose uptake into cells and reducing hepatic glucose output. Glimepiride also exhibits some extrapancreatic effects, potentially improving insulin sensitivity.

 

Key Features:

• Insulin Secretagogue: Directly stimulates the pancreas to increase insulin secretion.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Flexible Dosing: Available in various strengths, allowing for dose titration based on individual patient needs.
• Once-Daily Dosing: Can be taken once daily with breakfast or the first main meal.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glimepiride IP: 0.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It can be used as monotherapy (especially in newly diagnosed patients or those sensitive to higher doses) or in combination with other oral antidiabetic agents (e.g., Metformin) or insulin.

Glimepiride 0.5 mg Tablet

Product Description:

Glimepiride 0.5 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is used for the management of Type 2 Diabetes Mellitus in adults. This lower strength is particularly useful for initiating therapy, for patients requiring a milder dose to achieve glycemic control, or as part of a combination regimen.

 

Mechanism of Action: Glimepiride primarily works by stimulating the beta cells in the pancreas to release more insulin. It achieves this by binding to specific receptors on these cells, which leads to the closure of ATP-sensitive potassium channels. This triggers a cascade of events that cause the pancreatic beta cells to depolarize and release insulin. The increased insulin in the bloodstream helps to lower blood glucose by facilitating glucose uptake into cells and reducing hepatic glucose output. Glimepiride also exhibits some extrapancreatic effects, potentially improving insulin sensitivity.

 

Key Features:

• Insulin Secretagogue: Directly stimulates the pancreas to increase insulin secretion.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Flexible Dosing: Available in various strengths, allowing for dose titration based on individual patient needs.
• Once-Daily Dosing: Can be taken once daily with breakfast or the first main meal.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glimepiride IP: 0.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It can be used as monotherapy (especially in newly diagnosed patients or those sensitive to higher doses) or in combination with other oral antidiabetic agents (e.g., Metformin) or insulin.

Metformin Hydrochloride SR 1000 mg (SR) is an extended-release oral antidiabetic medication belonging to the biguanide class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults. The "SR" or "Sustained Release" designation means the active ingredient is released gradually into the body over an extended period, offering several advantages over immediate-release formulations.

Key Features:

• Sustained Blood Sugar Control: Provides consistent blood glucose lowering over 24 hours due to slow release.
• Reduced GI Side Effects: The extended-release nature often leads to fewer gastrointestinal issues like diarrhea, nausea, and abdominal discomfort compared to immediate-release metformin.
• Insulin Sensitizer: Directly addresses insulin resistance, a core problem in Type 2 Diabetes.
• Weight Neutrality / Modest Weight Loss: Unlike some other diabetes medications, it typically does not cause weight gain and may even lead to modest weight loss.
• Cardiovascular Benefits: Helps reduce the risk of certain diabetes-related complications, including heart attack and stroke.
• PCOS Management: Also used to improve insulin sensitivity and regulate hormones in women with Polycystic Ovary Syndrome (PCOS).

Metformin Hydrochloride SR 500 mg (SR) is an extended-release oral antidiabetic medication belonging to the biguanide class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults. The "SR" or "Sustained Release" designation means the active ingredient is released gradually into the body over an extended period, offering several advantages over immediate-release formulations.

Key Features:

• Sustained Blood Sugar Control: Provides consistent blood glucose lowering over 24 hours due to slow release.
• Reduced GI Side Effects: The extended-release nature often leads to fewer gastrointestinal issues like diarrhea, nausea, and abdominal discomfort compared to immediate-release metformin.
• Insulin Sensitizer: Directly addresses insulin resistance, a core problem in Type 2 Diabetes.
• Weight Neutrality / Modest Weight Loss: Unlike some other diabetes medications, it typically does not cause weight gain and may even lead to modest weight loss.
• Cardiovascular Benefits: Helps reduce the risk of certain diabetes-related complications, including heart attack and stroke.
• PCOS Management: Also used to improve insulin sensitivity and regulate hormones in women with Polycystic Ovary Syndrome (PCOS).
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Metformin Hydrochloride IP: 500 mg (as Sustained Release)
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults. Can be used as monotherapy or in combination with other oral antidiabetic agents or insulin.
• Polycystic Ovary Syndrome (PCOS): For improving insulin sensitivity, managing menstrual irregularities, and reducing androgen levels.
• Prevention of Type 2 Diabetes: In prediabetic individuals at high risk for developing Type 2 Diabetes, particularly those with a higher BMI.

Important Considerations:

• Take with Food: Best taken with the evening meal to optimize absorption and minimize gastrointestinal side effects.
• Swallow Whole: Do not crush, chew, or break the tablet, as this will disrupt the sustained-release mechanism.

Voglibose 0.3 mg tablets are an oral antidiabetic medication classified as an alpha-glucosidase inhibitor. It is primarily used for the management of Type 2 Diabetes Mellitus, particularly to control the rise in blood sugar levels after meals (postprandial hyperglycemia). This medication is often prescribed when diet, exercise, and other antidiabetic drugs (or their combinations) are insufficient to achieve desired glycemic control.

Mechanism of Action: Voglibose works in the small intestine by reversibly inhibiting alpha-glucosidase enzymes. These enzymes are responsible for breaking down complex carbohydrates (like starch, sucrose) into simpler sugars (like glucose) that can be absorbed into the bloodstream. By blocking these enzymes, Voglibose delays the digestion and absorption of carbohydrates, which in turn slows down and reduces the immediate spike in blood glucose levels after eating. It does not directly affect insulin secretion or insulin sensitivity.

Key Features:

• Targets Post-Meal Blood Sugar: Specifically designed to control blood glucose spikes that occur after meals.
• Unique Mechanism: Works by delaying carbohydrate digestion, making it complementary to other diabetes medications.
• Low Risk of Hypoglycemia (alone): Generally does not cause low blood sugar when used as monotherapy, as it doesn't stimulate insulin release.
• Oral Administration: Convenient tablet form for daily use.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Voglibose IP: 0.3 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve postprandial blood glucose levels in adults.
• Often used in combination with other oral hypoglycemic agents (e.g., Metformin, Sulfonylureas) or insulin when those therapies alone do not provide adequate control, especially of after-meal sugars.
• May also be used to prevent the progression of impaired glucose tolerance (pre-diabetes) to full-blown Type 2 Diabetes in high-risk individuals, as advised by a healthcare professional.

Important Considerations:

• Take Before Meals: It is crucial to take Voglibose tablets immediately before or with the first bite of each main meal for optimal efficacy.
• Gastrointestinal Side Effects: Common side effects include flatulence (gas), abdominal pain, diarrhea, and bloating, due to undigested carbohydrates fermenting in the colon. These often improve over time.
• Hypoglycemia Risk (with other drugs): While Voglibose alone rarely causes hypoglycemia, the risk increases significantly when taken with other antidiabetic medications that do stimulate insulin release (like sulfonylureas or insulin). If hypoglycemia occurs, it should be treated with plain glucose, as table sugar (sucrose) may not be absorbed quickly enough due to Voglibose's action.
• Contraindications: Not recommended for patients with inflammatory bowel disease, intestinal obstruction, or severe kidney impairment.
• Dietary Adherence: Continued adherence to a healthy diet and regular exercise is vital for overall diabetes management alongside Voglibose.

Voglibose 0.2 mg tablets are an oral antidiabetic medication classified as an alpha-glucosidase inhibitor. It is primarily used for the management of Type 2 Diabetes Mellitus, particularly to control the rise in blood sugar levels after meals (postprandial hyperglycemia). This medication is often prescribed when diet, exercise, and other antidiabetic drugs (or their combinations) are insufficient to achieve desired glycemic control.

Mechanism of Action: Voglibose works in the small intestine by reversibly inhibiting alpha-glucosidase enzymes. These enzymes are responsible for breaking down complex carbohydrates (like starch, sucrose) into simpler sugars (like glucose) that can be absorbed into the bloodstream. By blocking these enzymes, Voglibose delays the digestion and absorption of carbohydrates, which in turn slows down and reduces the immediate spike in blood glucose levels after eating. It does not directly affect insulin secretion or insulin sensitivity.

Key Features:

• Targets Post-Meal Blood Sugar: Specifically designed to control blood glucose spikes that occur after meals.
• Unique Mechanism: Works by delaying carbohydrate digestion, making it complementary to other diabetes medications.
• Low Risk of Hypoglycemia (alone): Generally does not cause low blood sugar when used as monotherapy, as it doesn't stimulate insulin release.
• Oral Administration: Convenient tablet form for daily use.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Voglibose IP: 0.2 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve postprandial blood glucose levels in adults.
• Often used in combination with other oral hypoglycemic agents (e.g., Metformin, Sulfonylureas) or insulin when those therapies alone do not provide adequate control, especially of after-meal sugars.
• May also be used to prevent the progression of impaired glucose tolerance (pre-diabetes) to full-blown Type 2 Diabetes in high-risk individuals, as advised by a healthcare professional.

Important Considerations:

• Take Before Meals: It is crucial to take Voglibose tablets immediately before or with the first bite of each main meal for optimal efficacy.
• Gastrointestinal Side Effects: Common side effects include flatulence (gas), abdominal pain, diarrhea, and bloating, due to undigested carbohydrates fermenting in the colon. These often improve over time.
• Hypoglycemia Risk (with other drugs): While Voglibose alone rarely causes hypoglycemia, the risk increases significantly when taken with other antidiabetic medications that do stimulate insulin release (like sulfonylureas or insulin). If hypoglycemia occurs, it should be treated with plain glucose, as table sugar (sucrose) may not be absorbed quickly enough due to Voglibose's action.
• Contraindications: Not recommended for patients with inflammatory bowel disease, intestinal obstruction, or severe kidney impairment.
• Dietary Adherence: Continued adherence to a healthy diet and regular exercise is vital for overall diabetes management alongside Voglibose.

Pioglitazone Hydrochloride 30 mg tablets are an oral antidiabetic medication belonging to the thiazolidinedione (TZD) class, often referred to as "glitazones." It is primarily used for the management of Type 2 Diabetes Mellitus in adults. This lower dose is particularly useful for patients requiring a milder insulin-sensitizing effect, or those more sensitive to fluid retention or weight gain associated with higher TZD doses.

Mechanism of Action: Pioglitazone works by improving the body's response to its own insulin. It acts as a selective agonist for Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor found in tissues critical for insulin action, such as fat cells, muscle, and liver. Activation of PPARγ modulates the transcription of genes involved in glucose and lipid metabolism, leading to:

• Increased Insulin Sensitivity: Cells become more responsive to insulin, enhancing glucose uptake and utilization by peripheral tissues.
• Reduced Hepatic Glucose Output: Decreases the amount of glucose produced and released by the liver. Unlike sulfonylureas, Pioglitazone does not stimulate insulin secretion from the pancreas, which helps reduce the risk of hypoglycemia when used as monotherapy.

Key Features:

• Insulin Sensitizer: Directly addresses insulin resistance, a core problem in Type 2 Diabetes.
• Improved Glycemic Control: Helps lower both fasting and post-meal blood sugar levels.
• Lower Dose Option: The 30 mg strength provides a gentler approach, potentially reducing side effects like weight gain and fluid retention compared to higher doses.
• Monotherapy or Combination: Can be used alone or in conjunction with other oral antidiabetic agents (e.g., Metformin, Sulfonylureas) or insulin.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Pioglitazone Hydrochloride IP equivalent to Pioglitazone: 30 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adult patients. Particularly suitable for those needing a milder insulin sensitizer or sensitive to TZD side effects.

Important Considerations:

• Fluid Retention/Heart Failure: Can cause fluid retention and may exacerbate or lead to congestive heart failure. Contraindicated in patients with symptomatic heart failure.
• Weight Gain: May cause weight gain, though typically less at lower doses.
• Bone Fractures: Increased risk of bone fractures, especially in women.
• Bladder Cancer: A debated, but potential, long-term risk.
• Liver Function: Liver function should be monitored periodically.

Pioglitazone Hydrochloride 15 mg tablets are an oral antidiabetic medication belonging to the thiazolidinedione (TZD) class, often referred to as "glitazones." It is primarily used for the management of Type 2 Diabetes Mellitus in adults. This lower dose is particularly useful for patients requiring a milder insulin-sensitizing effect, or those more sensitive to fluid retention or weight gain associated with higher TZD doses.

Mechanism of Action: Pioglitazone works by improving the body's response to its own insulin. It acts as a selective agonist for Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor found in tissues critical for insulin action, such as fat cells, muscle, and liver. Activation of PPARγ modulates the transcription of genes involved in glucose and lipid metabolism, leading to:

• Increased Insulin Sensitivity: Cells become more responsive to insulin, enhancing glucose uptake and utilization by peripheral tissues.
• Reduced Hepatic Glucose Output: Decreases the amount of glucose produced and released by the liver. Unlike sulfonylureas, Pioglitazone does not stimulate insulin secretion from the pancreas, which helps reduce the risk of hypoglycemia when used as monotherapy.

Key Features:

• Insulin Sensitizer: Directly addresses insulin resistance, a core problem in Type 2 Diabetes.
• Improved Glycemic Control: Helps lower both fasting and post-meal blood sugar levels.
• Lower Dose Option: The 7.5 mg strength provides a gentler approach, potentially reducing side effects like weight gain and fluid retention compared to higher doses.
• Monotherapy or Combination: Can be used alone or in conjunction with other oral antidiabetic agents (e.g., Metformin, Sulfonylureas) or insulin.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Pioglitazone Hydrochloride IP equivalent to Pioglitazone: 7.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adult patients. Particularly suitable for those needing a milder insulin sensitizer or sensitive to TZD side effects.

Important Considerations:

• Fluid Retention/Heart Failure: Can cause fluid retention and may exacerbate or lead to congestive heart failure. Contraindicated in patients with symptomatic heart failure.
• Weight Gain: May cause weight gain, though typically less at lower doses.
• Bone Fractures: Increased risk of bone fractures, especially in women.
• Bladder Cancer: A debated, but potential, long-term risk.
• Liver Function: Liver function should be monitored periodically.

Pioglitazone Hydrochloride 7.5 mg tablets are an oral antidiabetic medication belonging to the thiazolidinedione (TZD) class, often referred to as "glitazones." It is primarily used for the management of Type 2 Diabetes Mellitus in adults. This lower dose is particularly useful for patients requiring a milder insulin-sensitizing effect, or those more sensitive to fluid retention or weight gain associated with higher TZD doses.

Mechanism of Action: Pioglitazone works by improving the body's response to its own insulin. It acts as a selective agonist for Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor found in tissues critical for insulin action, such as fat cells, muscle, and liver. Activation of PPARγ modulates the transcription of genes involved in glucose and lipid metabolism, leading to:

• Increased Insulin Sensitivity: Cells become more responsive to insulin, enhancing glucose uptake and utilization by peripheral tissues.
• Reduced Hepatic Glucose Output: Decreases the amount of glucose produced and released by the liver. Unlike sulfonylureas, Pioglitazone does not stimulate insulin secretion from the pancreas, which helps reduce the risk of hypoglycemia when used as monotherapy.

Key Features:

• Insulin Sensitizer: Directly addresses insulin resistance, a core problem in Type 2 Diabetes.
• Improved Glycemic Control: Helps lower both fasting and post-meal blood sugar levels.
• Lower Dose Option: The 7.5 mg strength provides a gentler approach, potentially reducing side effects like weight gain and fluid retention compared to higher doses.
• Monotherapy or Combination: Can be used alone or in conjunction with other oral antidiabetic agents (e.g., Metformin, Sulfonylureas) or insulin.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Pioglitazone Hydrochloride IP equivalent to Pioglitazone: 7.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adult patients. Particularly suitable for those needing a milder insulin sensitizer or sensitive to TZD side effects.

Important Considerations:

• Fluid Retention/Heart Failure: Can cause fluid retention and may exacerbate or lead to congestive heart failure. Contraindicated in patients with symptomatic heart failure.
• Weight Gain: May cause weight gain, though typically less at lower doses.
• Bone Fractures: Increased risk of bone fractures, especially in women.
• Bladder Cancer: A debated, but potential, long-term risk.
• Liver Function: Liver function should be monitored periodically.

Glibenclamide 5 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose control.

Mechanism of Action: Glibenclamide works by stimulating the beta cells in the pancreas to release more insulin. It achieves this by binding to specific receptors on these cells, which leads to the closure of ATP-sensitive potassium channels and subsequent depolarization of the cell membrane. This triggers the influx of calcium ions, promoting the exocytosis (release) of insulin granules. The increased insulin then helps to lower blood glucose levels by facilitating glucose uptake into cells and reducing hepatic glucose production.

Key Features:

• Potent Insulin Secretagogue: Effectively stimulates the pancreas to release insulin.
• Effective Blood Glucose Control: Helps reduce both fasting and post-meal blood sugar levels.
• Cost-Effective: A well-established and generally affordable option for diabetes management.
• Convenient Dosing: Typically taken once or twice daily with meals.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glibenclamide IP: 5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It can be used as monotherapy or in combination with other oral antidiabetic agents (e.g., Metformin).

Important Considerations:

• Hypoglycemia Risk: Glibenclamide is known to have a higher risk of causing low blood sugar (hypoglycemia) compared to some newer diabetes medications due to its potent and sustained insulin-releasing effect. Patients should be thoroughly educated on symptoms of hypoglycemia and how to manage them.
• Weight Gain: May cause some weight gain.
• Renal/Hepatic Impairment: Use with caution and dose adjustment is often necessary in patients with kidney or liver impairment.
• Elderly Patients: Should be used with particular caution in elderly patients due to increased risk of prolonged hypoglycemia.

Glibenclamide 2.5 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose control.

Mechanism of Action: Glibenclamide works by stimulating the beta cells in the pancreas to release more insulin. It achieves this by binding to specific receptors on these cells, which leads to the closure of ATP-sensitive potassium channels and subsequent depolarization of the cell membrane. This triggers the influx of calcium ions, promoting the exocytosis (release) of insulin granules. The increased insulin then helps to lower blood glucose levels by facilitating glucose uptake into cells and reducing hepatic glucose production.

Key Features:

• Potent Insulin Secretagogue: Effectively stimulates the pancreas to release insulin.
• Effective Blood Glucose Control: Helps reduce both fasting and post-meal blood sugar levels.
• Cost-Effective: A well-established and generally affordable option for diabetes management.
• Convenient Dosing: Typically taken once or twice daily with meals.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glibenclamide IP: 2.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It can be used as monotherapy or in combination with other oral antidiabetic agents (e.g., Metformin).

Important Considerations:

• Hypoglycemia Risk: Glibenclamide is known to have a higher risk of causing low blood sugar (hypoglycemia) compared to some newer diabetes medications due to its potent and sustained insulin-releasing effect. Patients should be thoroughly educated on symptoms of hypoglycemia and how to manage them.
• Weight Gain: May cause some weight gain.
• Renal/Hepatic Impairment: Use with caution and dose adjustment is often necessary in patients with kidney or liver impairment.
• Elderly Patients: Should be used with particular caution in elderly patients due to increased risk of prolonged hypoglycemia.

Gliclazide 80 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight loss alone are insufficient to control blood sugar levels.

Mechanism of Action: Gliclazide primarily works by stimulating the beta cells in the pancreas to release more insulin. It binds to specific receptors on these cells, leading to a cascade of events that increase insulin secretion. This insulin then helps transport glucose from the bloodstream into cells, lowering blood sugar levels. Gliclazide also has some extrapancreatic effects, potentially improving peripheral insulin sensitivity and reducing hepatic glucose production.

Key Features:

• Insulin Secretagogue: Directly stimulates insulin release from the pancreas.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Standard Release: Provides a quick onset of action for blood sugar management.
• Convenient Dosing: Typically taken once or twice daily with meals.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Gliclazide IP: 80 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It is often used as a first-line treatment or in combination with other oral antidiabetic agents.

Important Considerations:

• Hypoglycemia Risk: As an insulin secretagogue, Gliclazide can cause low blood sugar (hypoglycemia). Patients should be educated on symptoms of hypoglycemia and carry a source of sugar.
• Weight Gain: May cause some weight gain.
• Renal/Hepatic Impairment: Use with caution and dose adjustment may be required in patients with kidney or liver problems.

Gliclazide 60 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight loss alone are insufficient to control blood sugar levels.

Mechanism of Action: Gliclazide primarily works by stimulating the beta cells in the pancreas to release more insulin. It binds to specific receptors on these cells, leading to a cascade of events that increase insulin secretion. This insulin then helps transport glucose from the bloodstream into cells, lowering blood sugar levels. Gliclazide also has some extrapancreatic effects, potentially improving peripheral insulin sensitivity and reducing hepatic glucose production.

Key Features:

• Insulin Secretagogue: Directly stimulates insulin release from the pancreas.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Standard Release: Provides a quick onset of action for blood sugar management.
• Convenient Dosing: Typically taken once or twice daily with meals.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Gliclazide IP: 60 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It is often used as a first-line treatment or in combination with other oral antidiabetic agents.

Important Considerations:

• Hypoglycemia Risk: As an insulin secretagogue, Gliclazide can cause low blood sugar (hypoglycemia). Patients should be educated on symptoms of hypoglycemia and carry a source of sugar.
• Weight Gain: May cause some weight gain.
• Renal/Hepatic Impairment: Use with caution and dose adjustment may be required in patients with kidney or liver problems.

Gliclazide 40 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight loss alone are insufficient to control blood sugar levels.

Mechanism of Action: Gliclazide primarily works by stimulating the beta cells in the pancreas to release more insulin. It binds to specific receptors on these cells, leading to a cascade of events that increase insulin secretion. This insulin then helps transport glucose from the bloodstream into cells, lowering blood sugar levels. Gliclazide also has some extrapancreatic effects, potentially improving peripheral insulin sensitivity and reducing hepatic glucose production.

Key Features:

• Insulin Secretagogue: Directly stimulates insulin release from the pancreas.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Standard Release: Provides a quick onset of action for blood sugar management.
• Convenient Dosing: Typically taken once or twice daily with meals.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Gliclazide IP: 40 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It is often used as a first-line treatment or in combination with other oral antidiabetic agents.

Important Considerations:

• Hypoglycemia Risk: As an insulin secretagogue, Gliclazide can cause low blood sugar (hypoglycemia). Patients should be educated on symptoms of hypoglycemia and carry a source of sugar.
• Weight Gain: May cause some weight gain.
• Renal/Hepatic Impairment: Use with caution and dose adjustment may be required in patients with kidney or liver problems.

Vildagliptin 50 mg + Metformin 500 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus. This tablet is typically prescribed when blood sugar levels are not adequately controlled by diet, exercise, or monotherapy. It combines two complementary antidiabetic agents:

1. Vildagliptin (DPP-4 Inhibitor / Gliptin): This component works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). By doing so, it enhances the levels of naturally occurring incretin hormones (like GLP-1 and GIP). These hormones increase glucose-dependent insulin secretion from the pancreas and reduce glucagon secretion, leading to better control of both fasting and post-meal blood sugar levels.

2. Metformin (Biguanide): This component primarily acts by:

   • Reducing the amount of glucose produced by the liver.
   • Decreasing the absorption of glucose from the intestines.
   • Improving the body's sensitivity to insulin, allowing cells to utilize glucose more efficiently.

This combination provides a comprehensive approach to diabetes management by improving both insulin release and the body's response to insulin, without typically causing weight gain.

Key Features:

• Dual-Action Formula: Combines two distinct mechanisms for robust blood glucose control.
• Glucose-Dependent Insulin Release: Vildagliptin stimulates insulin only when blood sugar is high, reducing hypoglycemia risk.
• Improved Insulin Sensitivity: Metformin component enhances the body's use of insulin.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen.
• Weight Neutrality: Generally does not cause weight gain.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Vildagliptin IP: 50 mg
• Metformin Hydrochloride IP: 500 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with metformin or vildagliptin monotherapy, or who are already being treated with both medications separately. It can also be used in combination with other diabetes medicines, including insulin.

Teneligliptin 20 mg + Metformin SR 1000 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus. This tablet is typically prescribed when diet, exercise, and monotherapy (either Metformin or a DPP-4 inhibitor) are insufficient to achieve adequate blood sugar control. It combines two different classes of antidiabetic agents for a synergistic effect:

 

1. Teneligliptin (DPP-4 Inhibitor / Gliptin): This component works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). By doing so, it prevents the breakdown of naturally occurring incretin hormones (like GLP-1 and GIP) in the body. Increased levels of these incretins lead to:

    

   • Enhanced insulin secretion from the pancreas in a glucose-dependent manner (i.e., only when blood sugar is high).
   • Reduced glucagon secretion, which in turn decreases glucose production by the liver.
   • This helps control both fasting and post-meal blood sugar levels.

2. Metformin (Biguanide) - Sustained Release (SR): The Metformin component acts by:

   •  Reducing the amount of glucose produced by the liver. 
   •  Decreasing the absorption of glucose from the intestines. 
   •  Improving the body's sensitivity to insulin, allowing cells to utilize glucose more efficiently. The Sustained Release (SR) formulation ensures a gradual and prolonged release of metformin, leading to more consistent blood sugar control throughout the day and often better gastrointestinal tolerability compared to immediate-release forms.

This combination offers a comprehensive approach to diabetes management by addressing both insulin resistance and the body's natural insulin and glucagon regulation.

 

Key Features:

• Dual-Action Formula: Combines two distinct mechanisms for robust blood glucose control.
• Targeted Glucose Regulation: Teneligliptin specifically improves post-meal glucose, while Metformin addresses liver glucose production and insulin sensitivity.
• Convenient Dosing: Fixed-dose combination in a single SR tablet improves patient adherence.
• Reduced Hypoglycemia Risk: Teneligliptin generally has a low risk of causing low blood sugar when used alone, and the SR formulation of Metformin also helps.
• Potential for Weight Neutrality/Loss: Metformin can lead to modest weight loss or be weight-neutral.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Teneligliptin 20 mg + Metformin SR 500 mg Tablet is a dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus. This tablet is typically prescribed when diet, exercise, and monotherapy (either Metformin or a DPP-4 inhibitor) are insufficient to achieve adequate blood sugar control. It combines two different classes of antidiabetic agents for a synergistic effect:

 

1. Teneligliptin (DPP-4 Inhibitor / Gliptin): This component works by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4). By doing so, it prevents the breakdown of naturally occurring incretin hormones (like GLP-1 and GIP) in the body. Increased levels of these incretins lead to:

    

   • Enhanced insulin secretion from the pancreas in a glucose-dependent manner (i.e., only when blood sugar is high).
   • Reduced glucagon secretion, which in turn decreases glucose production by the liver.
   • This helps control both fasting and post-meal blood sugar levels.

2. Metformin (Biguanide) - Sustained Release (SR): The Metformin component acts by:

   •  Reducing the amount of glucose produced by the liver. 
   •  Decreasing the absorption of glucose from the intestines. 
   •  Improving the body's sensitivity to insulin, allowing cells to utilize glucose more efficiently. The Sustained Release (SR) formulation ensures a gradual and prolonged release of metformin, leading to more consistent blood sugar control throughout the day and often better gastrointestinal tolerability compared to immediate-release forms.

This combination offers a comprehensive approach to diabetes management by addressing both insulin resistance and the body's natural insulin and glucagon regulation.

 

Key Features:

• Dual-Action Formula: Combines two distinct mechanisms for robust blood glucose control.
• Targeted Glucose Regulation: Teneligliptin specifically improves post-meal glucose, while Metformin addresses liver glucose production and insulin sensitivity.
• Convenient Dosing: Fixed-dose combination in a single SR tablet improves patient adherence.
• Reduced Hypoglycemia Risk: Teneligliptin generally has a low risk of causing low blood sugar when used alone, and the SR formulation of Metformin also helps.
• Potential for Weight Neutrality/Loss: Metformin can lead to modest weight loss or be weight-neutral.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Glimepiride 0.5 mg + Voglibose 0.3 mg + Metformin SR 1000 mg Tablet is an advanced triple-combination oral medication for the intensive management of Type 2 Diabetes Mellitus. It is prescribed for adults whose blood sugar levels are not adequately controlled by diet, exercise, or dual-drug therapies. This tablet combines three active pharmaceutical ingredients, each targeting a different aspect of glucose metabolism:

1. Glimepiride (Sulfonylurea): Acts on the pancreas to stimulate the release of more insulin, thereby lowering blood glucose levels.
2. Voglibose (Alpha-Glucosidase Inhibitor): Delays the digestion and absorption of carbohydrates in the small intestine, specifically reducing the rise in blood sugar levels after meals (postprandial hyperglycemia).
3. Metformin (Biguanide) - Sustained Release (SR): Reduces glucose production by the liver, decreases sugar absorption from the intestines, and improves the body's sensitivity to insulin. The SR formulation ensures a gradual release, providing sustained efficacy and often better gastrointestinal tolerability.

This comprehensive approach offers synergistic control over fasting and post-meal blood sugar, helping to achieve optimal glycemic targets.

Key Features:

• Triple-Action Formula: Provides multi-pronged attack on high blood sugar by addressing insulin secretion, carbohydrate digestion, and insulin sensitivity.
• Targeted Post-Meal Control: Voglibose specifically helps manage postprandial glucose spikes.
• Enhanced Efficacy: Ideal for patients inadequately controlled on fewer agents.
• Sustained Release Metformin: Offers prolonged action and potentially improved gastrointestinal comfort.
• Convenient Dosing: Combines three active ingredients into one tablet for improved patient adherence.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glimepiride IP: 0.5 mg
• Voglibose IP: 0.3 mg
• Metformin Hydrochloride IP: 1000 mg (as Sustained Release)
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with monotherapy or dual-combination therapies of metformin, glimepiride, and/or voglibose.

Additional Information:

• Production Capacity: unlimited

Glimepiride 0.5 mg + Voglibose 0.2 mg + Metformin SR 1000 mg Tablet is an advanced triple-combination oral medication for the intensive management of Type 2 Diabetes Mellitus. It is prescribed for adults whose blood sugar levels are not adequately controlled by diet, exercise, or dual-drug therapies. This tablet combines three active pharmaceutical ingredients, each targeting a different aspect of glucose metabolism:

1. Glimepiride (Sulfonylurea): Acts on the pancreas to stimulate the release of more insulin, thereby lowering blood glucose levels.
2. Voglibose (Alpha-Glucosidase Inhibitor): Delays the digestion and absorption of carbohydrates in the small intestine, specifically reducing the rise in blood sugar levels after meals (postprandial hyperglycemia).
3. Metformin (Biguanide) - Sustained Release (SR): Reduces glucose production by the liver, decreases sugar absorption from the intestines, and improves the body's sensitivity to insulin. The SR formulation ensures a gradual release, providing sustained efficacy and often better gastrointestinal tolerability.

This comprehensive approach offers synergistic control over fasting and post-meal blood sugar, helping to achieve optimal glycemic targets.

Key Features:

• Triple-Action Formula: Provides multi-pronged attack on high blood sugar by addressing insulin secretion, carbohydrate digestion, and insulin sensitivity.
• Targeted Post-Meal Control: Voglibose specifically helps manage postprandial glucose spikes.
• Enhanced Efficacy: Ideal for patients inadequately controlled on fewer agents.
• Sustained Release Metformin: Offers prolonged action and potentially improved gastrointestinal comfort.
• Convenient Dosing: Combines three active ingredients into one tablet for improved patient adherence.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glimepiride IP: 0.5 mg
• Voglibose IP: 0.2 mg
• Metformin Hydrochloride IP: 1000 mg (as Sustained Release)
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with monotherapy or dual-combination therapies of metformin, glimepiride, and/or voglibose.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

Empagliflozin 12.5 mg & Metformin 1000 mg Tablet is a combination oral medication for the comprehensive management of Type 2 Diabetes Mellitus. It is prescribed when blood sugar levels are not adequately controlled by diet, exercise, and single-agent therapy. This tablet combines two distinct antidiabetic agents to offer a synergistic effect:

1. Empagliflozin (SGLT2 Inhibitor): Works in the kidneys to block glucose reabsorption, leading to its excretion in urine. This lowers blood sugar and provides significant cardiovascular and renal protective benefits, reducing the risk of heart failure hospitalizations and kidney disease progression.
2. Metformin (Biguanide): Reduces glucose production by the liver, decreases intestinal glucose absorption, and enhances the body's sensitivity to insulin.

This dual approach targets different pathways of glucose regulation, leading to improved glycemic control and vital organ protection.

Key Features:

• Powerful Dual-Action: Combines two effective mechanisms for superior blood sugar control.
• Cardio-Renal Protection: Empagliflozin component reduces risk of cardiovascular death, heart failure hospitalization, and kidney disease progression.
• Insulin-Independent & Insulin-Sensitizing: Empagliflozin works independently of insulin, while Metformin improves insulin utilization.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen.
• Potential for Weight Loss: May contribute to modest weight reduction.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Empagliflozin IP: 12.5 mg
• Metformin Hydrochloride IP: 1000 mg (often in extended-release form)
• Excipients: q.s.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

The Empagliflozin 12.5 mg & Metformin 500 mg Tablet is a combination oral medication for the comprehensive management of Type 2 Diabetes Mellitus. It is prescribed when blood sugar levels are not adequately controlled by diet, exercise, and single-agent therapy. This tablet combines two distinct antidiabetic agents to offer a synergistic effect:

1. Empagliflozin (SGLT2 Inhibitor): Works in the kidneys to block glucose reabsorption, leading to its excretion in urine. This lowers blood sugar and provides significant cardiovascular and renal protective benefits, reducing the risk of heart failure hospitalizations and kidney disease progression.
2. Metformin (Biguanide): Reduces glucose production by the liver, decreases intestinal glucose absorption, and enhances the body's sensitivity to insulin.

This dual approach targets different pathways of glucose regulation, leading to improved glycemic control and vital organ protection.

Key Features:

• Powerful Dual-Action: Combines two effective mechanisms for superior blood sugar control.
• Cardio-Renal Protection: Empagliflozin component reduces risk of cardiovascular death, heart failure hospitalization, and kidney disease progression.
• Insulin-Independent & Insulin-Sensitizing: Empagliflozin works independently of insulin, while Metformin improves insulin utilization.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen.
• Potential for Weight Loss: May contribute to modest weight reduction.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Empagliflozin IP: 12.5 mg
• Metformin Hydrochloride IP: 500 mg (often in extended-release form)
• Excipients: q.s.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

The Empagliflozin 12.5 mg & Metformin 850 mg Tablet is a combination oral medication for the comprehensive management of Type 2 Diabetes Mellitus. It is prescribed when blood sugar levels are not adequately controlled by diet, exercise, and single-agent therapy. This tablet combines two distinct antidiabetic agents to offer a synergistic effect:

1. Empagliflozin (SGLT2 Inhibitor): Works in the kidneys to block glucose reabsorption, leading to its excretion in urine. This lowers blood sugar and provides significant cardiovascular and renal protective benefits, reducing the risk of heart failure hospitalizations and kidney disease progression.
2. Metformin (Biguanide): Reduces glucose production by the liver, decreases intestinal glucose absorption, and enhances the body's sensitivity to insulin.

This dual approach targets different pathways of glucose regulation, leading to improved glycemic control and vital organ protection.

Key Features:

• Powerful Dual-Action: Combines two effective mechanisms for superior blood sugar control.
• Cardio-Renal Protection: Empagliflozin component reduces risk of cardiovascular death, heart failure hospitalization, and kidney disease progression.
• Insulin-Independent & Insulin-Sensitizing: Empagliflozin works independently of insulin, while Metformin improves insulin utilization.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen.
• Potential for Weight Loss: May contribute to modest weight reduction.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Empagliflozin IP: 12.5 mg
• Metformin Hydrochloride IP: 850 mg (often in extended-release form)
• Excipients: q.s.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

Empagliflozin 10 mg is an oral medication belonging to the SGLT2 inhibitor class. It is primarily used for the management of Type 2 Diabetes Mellitus. Beyond glucose control, it offers significant cardiovascular and renal benefits, reducing the risk of cardiovascular death, hospitalization for heart failure, and progression of chronic kidney disease.

Mechanism of Action: Empagliflozin works in the kidneys by blocking the sodium-glucose co-transporter 2 (SGLT2) protein. This action prevents the kidneys from reabsorbing glucose back into the bloodstream, leading to increased excretion of glucose in the urine. This process lowers blood sugar levels independently of insulin. It also promotes the excretion of excess sodium and water, contributing to its cardiovascular and renal protective effects.

Key Features:

• Multifaceted Benefits: Lowers blood sugar, reduces cardiovascular death and hospitalization for heart failure, and slows chronic kidney disease progression.
• Insulin-Independent Action: Works differently from many other diabetes drugs, effective even when insulin production is compromised.
• Weight Neutral/Loss Potential: May contribute to modest weight loss.
• Once-Daily Dosing: Convenient for patient adherence.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Empagliflozin IP: 10 mg
• Excipients: q.s. (quantity sufficient)

Indications:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older.
• Cardiovascular Risk Reduction: To reduce the risk of cardiovascular death in adults with Type 2 Diabetes and established cardiovascular disease.
• Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (with reduced or preserved ejection fraction).
• Chronic Kidney Disease: To reduce the risk of worsening of kidney disease, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease.

Additional Information:

• Production Capacity: Unlimited
• Delivery Time: 4-6 weeks

The Metformin 500 mg + Glimepiride 2 mg Tablet is a fixed-dose combination medication specifically designed for the enhanced management of Type 2 Diabetes Mellitus. This combination is typically prescribed when diet, exercise, and single-agent therapy (either Metformin or Glimepiride alone) do not adequately control blood sugar levels.

This powerful combination leverages the distinct mechanisms of two different classes of antidiabetic drugs:

1. Metformin (Biguanide):

   • Reduces glucose production by the liver.
   • Decreases intestinal glucose absorption.
   • Increases insulin sensitivity, allowing the body's cells to use insulin more effectively.

2. Glimepiride (Sulfonylurea):

   • Stimulates the pancreas to release more insulin. This action helps to lower blood glucose by increasing the amount of insulin available to facilitate glucose uptake by cells.

By combining these two agents, the tablet provides a synergistic effect, offering more comprehensive blood sugar control than either medication alone. This dual approach helps address different facets of Type 2 Diabetes pathophysiology, leading to better glycemic outcomes.

Key Features:

• Dual-Action Formula: Combines two distinct antidiabetic mechanisms for superior blood glucose control.
• Enhanced Glycemic Control: More effective in lowering HbA1c (a measure of long-term blood sugar control) compared to monotherapy.
• Convenient Dosing: Fixed-dose combination simplifies medication regimen for patients.
• Reduced Risk of Complications: Effective blood sugar management helps reduce the risk of long-term diabetes complications like kidney damage, nerve problems, and eye damage.
• Available in SR/PR Forms: Often available as Sustained-Release (SR) or Prolonged-Release (PR) tablets for once-daily dosing and consistent blood sugar management throughout the day.
• Quality Assured: Manufactured in WHO-GMP certified facilities, ensuring product quality and safety.

Composition (per tablet):

• Metformin Hydrochloride IP: 500 mg (often in SR/PR form)
• Glimepiride IP: 2 mg
• Excipients: q.s. (quantity sufficient)

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with either metformin or glimepiride monotherapy, or who are already being treated with both medications separately.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

Metformin 850 mg tablets are an oral medication for Type 2 Diabetes Mellitus and Polycystic Ovary Syndrome (PCOS). As a biguanide, it lowers blood sugar by:

• Reducing liver glucose production.
• Decreasing intestinal glucose absorption.
• Improving insulin sensitivity.

Key Features:

• Effective Blood Sugar Control: Manages high glucose levels.
• Dual-Action Mechanism: Works on liver, intestines, and cells.
• Weight Neutral/Loss Potential: Doesn't cause weight gain; may aid modest weight loss.
• PCOS Management: Addresses insulin resistance in PCOS.
• Available Forms: Immediate-Release and Extended-Release (SR/XR).
• Quality Assurance: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Metformin Hydrochloride IP: 850 mg

Indications:

• Type 2 Diabetes Mellitus: Monotherapy or combination therapy.
• Polycystic Ovary Syndrome (PCOS): For insulin resistance and hormonal balance.
• Type 2 Diabetes Prevention: For at-risk individuals.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

Metformin 500 mg tablets are an oral medication for Type 2 Diabetes Mellitus and Polycystic Ovary Syndrome (PCOS). As a biguanide, it lowers blood sugar by:
Reducing liver glucose production.
Decreasing intestinal glucose absorption.
Improving insulin sensitivity.
Key Features:
Effective Blood Sugar Control: Manages high glucose levels.
Dual-Action Mechanism: Works on liver, intestines, and cells.
Weight Neutral/Loss Potential: Doesn't cause weight gain; may aid modest weight loss.
PCOS Management: Addresses insulin resistance in PCOS.
Available Forms: Immediate-Release and Extended-Release (SR/XR).
Quality Assurance: Manufactured in WHO-GMP certified facilities.
Composition (per tablet):
Metformin Hydrochloride IP: 500 mg
Indications:
Type 2 Diabetes Mellitus: Monotherapy or combination therapy.
Polycystic Ovary Syndrome (PCOS): For insulin resistance and hormonal balance.
Type 2 Diabetes Prevention: For at-risk individuals.

Additional Information:

• Production Capacity: unlimited
• Delivery Time: 4-6 weeks

Omeprazole Delayed Release Capsules USP 40mg contain the active substance omeprazole, a widely recognized proton pump inhibitor (PPI) designed to effectively reduce the production of acid in the stomach. These capsules are formulated for delayed release, ensuring the omeprazole is protected from stomach acid and absorbed in the small intestine for optimal efficacy. Omeprazole 40mg is primarily indicated for the treatment of various acid-related conditions, including severe gastroesophageal reflux disease (GERD) with erosive esophagitis (inflammation and damage to the esophagus), gastric ulcers, duodenal ulcers, and Zollinger-Ellison syndrome, a condition where the stomach produces excessive acid due to a tumor. It is also used in combination with antibiotics to eradicate Helicobacter pylori (H. pylori) infection, which can cause ulcers. Common dosages vary based on the condition being treated; for erosive esophagitis, 20 mg or 40 mg once daily for 4-8 weeks is typical, while for gastric ulcers, 40 mg once daily for 4-8 weeks may be prescribed. For Zollinger-Ellison syndrome, the initial dose is often 60 mg once daily, adjusted as needed. Capsules should be swallowed whole and not crushed or chewed. Omeprazole Delayed Release Capsules should be stored at controlled room temperature, generally between 20°C to 25°C (68°F to 77°F), protected from light and moisture, and kept in their original packaging to maintain stability. India is a major hub for pharmaceutical manufacturing and export, with numerous reputable companies producing Omeprazole Delayed Release Capsules USP 40mg.

Tolbutamide 500 mg tablets are an oral antidiabetic medication that belongs to the first-generation sulfonylurea class. It is primarily used for the management of Type 2 Diabetes Mellitus in adults, particularly when diet, exercise, and weight loss alone are insufficient to control blood sugar levels.

Mechanism of Action: Tolbutamide works by stimulating the beta cells in the pancreas to release more insulin. It binds to specific receptors on these cells (sulfonylurea receptors or SUR1), which leads to the closure of ATP-sensitive potassium channels. This causes depolarization of the beta cell membrane, triggering an influx of calcium ions, which in turn promotes the exocytosis (release) of insulin-containing granules. The increased insulin in the bloodstream helps to lower blood glucose levels by facilitating glucose uptake into cells and inhibiting glucose production by the liver.

Key Features:

• Insulin Secretagogue: Directly stimulates insulin release from functioning pancreatic beta cells.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Cost-Effective: A well-established and generally affordable option for diabetes management.
• Oral Administration: Convenient tablet form for daily use.
• Quality Assured: Manufactured in WHO-GMP certified facilities.